NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics today said that it completed its $12 million Series B equity financing round to support the commercial expansion of its RNA biomarker technology.

New Leaf Venture Partners and existing investor Morningside Ventures participated in the round.

The funding will go toward further commercialization of Advanced Cell's RNAscope-based products and services into the life science research market, as well as toward acceleration of RNAscope into the clinical diagnostics space.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.